Compare HLI & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLI | UTHR |
|---|---|---|
| Founded | 1972 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 20.3B |
| IPO Year | 2015 | 1999 |
| Metric | HLI | UTHR |
|---|---|---|
| Price | $179.65 | $488.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 12 |
| Target Price | $205.38 | ★ $495.08 |
| AVG Volume (30 Days) | 367.8K | ★ 424.3K |
| Earning Date | 10-30-2025 | 10-29-2025 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | ★ 26.59 | 16.08 |
| EPS | 6.19 | ★ 26.38 |
| Revenue | $2,565,361,000.00 | ★ $3,128,400,000.00 |
| Revenue This Year | $15.23 | $13.64 |
| Revenue Next Year | $13.29 | $5.78 |
| P/E Ratio | $29.04 | ★ $18.55 |
| Revenue Growth | ★ 21.00 | 13.50 |
| 52 Week Low | $137.99 | $266.98 |
| 52 Week High | $211.78 | $492.62 |
| Indicator | HLI | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 68.10 |
| Support Level | $171.77 | $470.13 |
| Resistance Level | $178.75 | $492.62 |
| Average True Range (ATR) | 3.98 | 10.72 |
| MACD | 1.22 | -0.53 |
| Stochastic Oscillator | 81.63 | 89.55 |
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.